Literature DB >> 25919507

Sequential Treatment with SDF-1 and BMP-2 Potentiates Bone Formation in Calvarial Defects.

Hee-Don Hwang1, Jung-Tae Lee1, Jeong-Tae Koh2, Hong-Moon Jung1, Heon-Jin Lee3, Tae-Geon Kwon1.   

Abstract

Stromal cell-derived factor-1 (SDF-1) protein and its receptor, CXCR-4, play an important role in tissue repair and regeneration in various organs, including the bone. SDF-1 is indispensable for bone morphogenetic protein-2 (BMP-2)-induced osteogenic differentiation. However, SDF-1 is not needed after the osteogenic induction has been activated. Since the precise condition for the additive effects of combined DF-1 and BMP-2 in bone healing had not been fully investigated, we aimed to determine the optimal conditions for SDF-1- and BMP-2-mediated bone regeneration. We examined the in vitro osteoblastic differentiation and cell migration after sequential treatments with SDF-1 and BMP-2. Based on the in vitro additive effects of SDF-1 and BMP-2, the critical size defects of mice calvaria were treated with these cytokines in various sequences. Phosphate buffered saline (PBS)-, SDF-1-, or BMP-2-soaked collagen scaffolds were implanted into the calvarial defects (n=36). Periodic percutaneous injections of PBS or the cytokine SDF-1 and BMP-2 into the implanted scaffolds were performed on days 3 and 6, postoperatively. Six experimental groups were used according to the types and sequences of the cytokine treatments. After 28 days, the mice were euthanized and bone formation was evaluated with microcomputed tomography and histology. The molecular mechanism of the additive effect of SDF-1 and BMP-2 was evaluated by analyzing intracellular signal transduction through Smad and Erk phosphorylation. The in vitro experiments revealed that, among all the treatments, the treatment with BMP-2 after SDF-1 showed the strongest osteoblastic differentiation and enhanced cell migration. Similarly, in the animal model, the treatment with SDF-1 followed by BMP-2 treatment showed the highest degree of new bone regeneration than any other groups, including the one with continuous BMP-2 treatment. This new bone formation can be partially explained by the activation of Smad and Erk pathways and enhanced cell migration. These results suggest that sequential treatment with the cytokines, SDF-1 and BMP-2, may be a promising strategy for accelerating bone regeneration in critical size defects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25919507     DOI: 10.1089/ten.TEA.2014.0571

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  10 in total

Review 1.  Bioinspired Collagen Scaffolds in Cranial Bone Regeneration: From Bedside to Bench.

Authors:  Justine C Lee; Elizabeth J Volpicelli
Journal:  Adv Healthc Mater       Date:  2017-06-06       Impact factor: 9.933

Review 2.  Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants.

Authors:  Jordan Raphel; Mark Holodniy; Stuart B Goodman; Sarah C Heilshorn
Journal:  Biomaterials       Date:  2016-01-18       Impact factor: 12.479

Review 3.  Role of MicroRNA-141 in the Aging Musculoskeletal System: A Current Overview.

Authors:  Babatunde Fariyike; Quante Singleton; Monte Hunter; William D Hill; Carlos M Isales; Mark W Hamrick; Sadanand Fulzele
Journal:  Mech Ageing Dev       Date:  2018-12-07       Impact factor: 5.432

Review 4.  Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology.

Authors:  William Gilbert; Robert Bragg; Ahmed M Elmansi; Meghan E McGee-Lawrence; Carlos M Isales; Mark W Hamrick; William D Hill; Sadanand Fulzele
Journal:  Cytokine       Date:  2019-07-20       Impact factor: 3.861

5.  Age-associated changes in microRNAs affect the differentiation potential of human mesenchymal stem cells: Novel role of miR-29b-1-5p expression.

Authors:  Nada H Eisa; Periyasamy T Sudharsan; Sergio Mas Herrero; Samuel A Herberg; Brian F Volkman; Alexandra Aguilar-Pérez; Dmitry Kondrikov; Ahmed M Elmansi; Charles Reitman; Xingming Shi; Sadanand Fulzele; Meghan E McGee-Lawrence; Carlos M Isales; Mark W Hamrick; Maribeth H Johnson; Jie Chen; William D Hill
Journal:  Bone       Date:  2021-08-14       Impact factor: 4.398

6.  Preclinical therapies to prevent or treat fracture non-union: A systematic review.

Authors:  Philippa M Bennett; Sarah K Stewart; Janine Dretzke; Danai Bem; Jowan G Penn-Barwell
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

7.  A Novel Strategy to Enhance Microfracture Treatment With Stromal Cell-Derived Factor-1 in a Rat Model.

Authors:  Taylor Mustapich; John Schwartz; Pablo Palacios; Haixiang Liang; Nicholas Sgaglione; Daniel A Grande
Journal:  Front Cell Dev Biol       Date:  2021-02-04

8.  Co‑delivery and controlled release of stromal cell‑derived factor‑1α chemically conjugated on collagen scaffolds enhances bone morphogenetic protein‑2‑driven osteogenesis in rats.

Authors:  Haipeng Sun; Jinming Wang; Feilong Deng; Yun Liu; Xiumei Zhuang; Jiayun Xu; Long Li
Journal:  Mol Med Rep       Date:  2016-05-24       Impact factor: 2.952

9.  Omega-3 Fatty Acids Supplementation Differentially Modulates the SDF-1/CXCR-4 Cell Homing Axis in Hypertensive and Normotensive Rats.

Authors:  Luiza Halmenschlager; Alexandre Machado Lehnen; Aline Marcadenti; Melissa Medeiros Markoski
Journal:  Nutrients       Date:  2017-08-01       Impact factor: 5.717

Review 10.  Delivery of stromal cell-derived factor 1α for in situ tissue regeneration.

Authors:  Wen Zhao; Kaixiang Jin; Jiaojiao Li; Xuefeng Qiu; Song Li
Journal:  J Biol Eng       Date:  2017-06-29       Impact factor: 4.355

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.